A Phase III, Randomized, Double-Blind, Placebo Controlled Clinical Trial Evaluating the Benefits and Mechanism Of Action Of Angiotensin-II Receptor Blocker On Cardiovascular Remodeling In Patients With Repaired Coarctation Of Aorta

Mayo Clinic

Summary

The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * B/S1 hypertension * SBP 100-139 average based on 3 office measurements. * Age 18 or Older * Previous COA Repair Exclusion Criteria: * Currently on beta blocker (BB) therapy * Pregnancy/lactating * eGFR\<30 * Hyperkalemia (serum potassium \>5.5mmol/L) * Severe Aortic or Mitral valve stenosis or regurgitation * Epicardial CAD diagnosis * Received antihypertensive medications within the past year

Interventions

Drug
Losartan
50mg administered orally once daily for 52 weeks.
Drug
Amlodipine
5mg Amlodipine administered orally once daily for 52 weeks.
Drug
Placebo
Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.

Location

Mayo Clinic in Rochester
Rochester, Minnesota
RSTACHDRESPRG@mayo.edu (507) 293-2565

A Phase III, Randomized, Double-Blind, Placebo Controlled Clinical Trial Evaluating the Benefits and Mechanism Of Action Of Angiotensin-II Receptor Blocker On Cardiovascular Remodeling In Patients With Repaired Coarctation Of Aorta

Summary

Eligibility

Interventions

Location

Run this study?

Details

Conditions